Saturday, February 2, 2019

The U.S. Food and Drug Administration on Friday declined to approve Alkermes Plc's opioid-based depression treatment, citing the need for additional data to prove the effectiveness of the drug.


from Reuters: Health News https://reut.rs/2Bhi3eG

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner